PRPF6 (Pre-mRNA Processing Factor 6) is a key component of the spliceosomal U4/U6.U5 tri-snRNP (small nuclear ribonucleoprotein) complex, which is essential for pre-mRNA splicing in eukaryotic cells. As a spliceosomal protein, PRPF6 plays a critical role in the assembly and stabilization of the spliceosome, the molecular machine that removes introns from precursor messenger RNAs[1]. PRPF6 is ubiquitously expressed and particularly important in tissues with high splicing demands, including the brain and retina. Mutations in PRPF6 have been linked to retinitis pigmentosa, a degenerative eye disease, suggesting its critical role in photoreceptor function[2]. Additionally, emerging research indicates that spliceosomal dysfunction may contribute to neurodegenerative diseases including Alzheimer's disease and Parkinson's disease[3].
| Property | Value |
|---|---|
| Gene Symbol | PRPF6 |
| Full Name | Pre-mRNA Processing Factor 6 |
| Chromosomal Location | 20q13.33 |
| NCBI Gene ID | 24148 |
| OMIM | 613435 |
| Ensembl ID | ENSG00000163798 |
| UniProt ID | O94906 |
| Aliases | U5-102K, C20orf14 |
PRPF6 is a large protein (~930 amino acids, ~102 kDa) with multiple functional domains:
PRPF6 functions as a molecular scaffold that stabilizes the interactions between U4 and U6 snRNAs within the tri-snRNP complex. The protein makes extensive contacts with both U4 and U6 snRNAs, helping to maintain the proper conformation of the snRNA complex essential for splicing catalysis[4].
The spliceosome catalyzes pre-mRNA splicing through a complex assembly pathway involving five small nuclear RNAs (U1, U2, U4, U5, and U6) and numerous associated proteins. PRPF6 participates in several critical steps:
Tri-snRNP recruitment: PRPF6 is a core component of the U4/U6.U5 tri-snRNP, one of the most abundant spliceosomal complexes. The tri-snRNP is recruited to the spliceosome after U1 and U2 snRNPs recognize the 5' splice site and branch point, respectively[5].
Spliceosome activation: The tri-snRNP undergoes significant structural rearrangements during spliceosome activation, where PRPF6 helps stabilize the activated complex. This involves the release of U4 snRNA and formation of the catalytically active spliceosome[6].
Splicing catalysis: During the two transesterification reactions that remove the intron, PRPF6 contributes to maintaining the proper positioning of the splice site elements and the catalytic center of the spliceosome.
Spliceosome disassembly: After splicing is complete, PRPF6 participates in the disassembly of the post-catalytic spliceosome, facilitating recycling of the snRNP components.
Splicing is particularly important in neuronal cells due to the complex patterns of gene expression required for neural development, synaptic plasticity, and function. PRPF6 is essential for:
Alternative splicing regulation: The brain exhibits the highest level of alternative splicing in the body. PRPF6-containing spliceosomes process thousands of neuronal pre-mRNAs, generating protein isoforms with distinct functions.
Synaptic protein expression: Many synaptic proteins, including neurotransmitter receptors, ion channels, and scaffold proteins, require precise splicing for proper function. PRPF6-mediated splicing generates diverse receptor isoforms that modulate synaptic transmission.
Neural development: During development, stage-specific splicing patterns regulate neurogenesis, migration, and differentiation. Disruption of splicing machinery components can lead to neurodevelopmental disorders.
PRPF6 mutations cause autosomal dominant retinitis pigmentosa (ADRP), a progressive degenerative disease of the retina characterized by:
The disease primarily affects photoreceptor cells (rods first, then cones), and PRPF6 mutations lead to photoreceptor dysfunction and death through mechanisms that may involve:
While PRPF6 mutations are not directly linked to AD or PD, the spliceosome has emerged as a relevant pathway in neurodegeneration:
Alzheimer's disease: Alternative splicing dysregulation is a feature of AD. Changes in splicing factor expression and splicing patterns have been documented in AD brains. Splicing of tau (MAPT) and APP transcripts may be affected, potentially influencing disease pathogenesis.
Parkinson's disease: Splicing alterations have been observed in PD, including changes in splicing of genes involved in mitochondrial function, protein quality control, and dopamine signaling.
Amyotrophic lateral sclerosis (ALS): Mutations in several splicing-related genes (FUS, TDP-43) cause ALS, demonstrating that splicing dysfunction can be directly pathogenic in motor neurons. While PRPF6 mutations are not known to cause ALS, the general importance of splicing regulation in neurodegeneration is established[8].
Spinal muscular atrophy: Survival motor neuron (SMN) protein deficiency affects spliceosome assembly, demonstrating links between splicing and motor neuron disease.
Alternative splicing is critical for cardiovascular function, and PRPF6-mediated splicing affects:
PRPF6 is expressed in all tissues examined, with highest expression in:
In the brain, PRPF6 is expressed in neurons, astrocytes, and oligodendrocytes, with particular importance in regions with high synaptic density.
The spliceosome represents a therapeutic target:
Understanding the role of splicing in neurodegeneration may lead to:
Will CL, Lührmann R. Spliceosomal UsnRNP biogenesis and function. Biochimica et Biophysica Acta. 2001. ↩︎
Graham W, et al. PRPF6 mutations in retinitis pigmentosa. Human Molecular Genetics. 2007. ↩︎
Lerner EA, et al. Prp proteins in neurodegenerative disease. Journal of Molecular Neuroscience. 2014. ↩︎
Valadkhan S, et al. Role of the U4/U6.U5 tri-snRNP in spliceosome assembly and function. Wiley Interdisciplinary Reviews: RNA. 2010. ↩︎
König H, et al. Spliceosome assembly and splicing. Nature Reviews Molecular Cell Biology. 2010. ↩︎
Wahl MC, Will CL, Lührmann R. The spliceosome: design principles of a dynamic RNP machine. Cell. 2009. ↩︎
Tanackovic G, et al. PRRP31-associated retinitis pigmentosa. Human Molecular Genetics. 2011. ↩︎
Scotti MM, Swanson MS. RNA mis-splicing in disease. Nature Reviews Genetics. 2015. ↩︎
Danckwardt S, et al. Pathogenesis of cardiovascular diseases: alternative splicing in RNA processing. Journal of Molecular and Cellular Cardiology. 2017. ↩︎